Kymera Therapeutics Inc. Common Stock vs UDR Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while UDR Inc. Common Stock trades at $33.9 (market cap $10.93B). The key difference: UDR Inc. Common Stock is the larger of the two by market cap, and UDR Inc. Common Stock pays a 5.12% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and UDR Inc. Common Stock for 0 Days on average.
| KYMR | UDR | |
|---|---|---|
Market Cap | $8.87B | $10.93B |
Volume | 779,107 | 2,607,837 |
Sector | Health | Real Estate |
52-Week High | $127.31 | $41.24 |
52-Week Low | $55.80 | $33.27 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $8.26B | $16.96B |
Dividend Yield | — | 5.12% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →UDR, Inc. is a self-administered real estate investment trust that owns, operates, develops, and redevelops multifamily apartment communities across targeted US markets. The company generates income primarily through leasing apartment homes, with a portfolio concentrated in coastal and Sunbelt metropolitan areas.
Read more on UDR →